The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Open accessAbstract
Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in type 2 diabetes mellitus (T2DM). The overarching hypothesis is that hyperglycemia and glucotoxicity are upstream of all other complications seen in diabetes. The aim of this study was to investigate effects of empagliflozin on glucotoxicity, β-cell function, inflammation, oxidative stress and endothelial dysfunction in Zucker diabetic fatty (ZDF) rats. Male ZDF rats were used as a model of T2DM (35 diabetic ZDF‐Lepr fa/fa and 16 ZDF-Lepr +/+ controls). Empagliflozin (10 and 30 mg/kg/d) was administered via drinking water for 6 weeks. Treatment with empagliflozin restored glycemic control. Empagliflozin improved endothelial function (thoracic aorta) and reduced oxidative stress in the aorta and in blood of diabetic rats. Inflammation and glucotoxicity (AGE/RAGE signaling) were epigenetically prevented by SGLT2i treatment (ChIP). Linear regression analysis revealed a significant inverse correlation of endothelial function with HbA1c, whereas leukocyte-dependent oxidative burst and C-reactive protein (CRP) were positively correlated with HbA1c. Viability of hyperglycemic endothelial cells was pleiotropically improved by SGLT2i. Empagliflozin reduces glucotoxicity and thereby prevents the development of endothelial dysfunction, reduces oxidative stress and exhibits anti-inflammatory effects in ZDF rats, despite persisting hyperlipidemia and hyperinsulinemia. Our preclinical observations provide insights into the mechanisms by which empagliflozin reduces cardiovascular mortality in humans (EMPA-REG trial).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“So far, neither therapy with a dipeptidyl peptidase 4 inhibitor nor with a glucagon-like peptide-1 analogue showed a similar reduction in cardiovascular and overall mortality in T2DM patients with proven cardiovascular risk [23,24].”
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690 · cited 1×
“well as exhaustion of insulin content [44,45].”
Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus
Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M., Thaiss, F., Stahl, R. A. K., Warnholtz, A., et al. (2001) · Circulation Research · doi:10.1161/01.res.88.2.e14 · Cited by 1,187
Self-citationActivation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE
Wautier, M.-P., Chappey, O., Corda, S., Stern, D. M., Schmidt, A. M., & Wautier, J.-L. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.5.e685 · Cited by 1,072
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · cited 1×
“old ZDF rats [67], for empagliflozin in obese rats [26] and for dapagliflozin therapy in T2DM patients [68].”
Fleming, I., Fisslthaler, B., Dimmeler, S., Kemp, B. E., & Busse, R. (2001) · Circulation Research · doi:10.1161/hh1101.092677 · Cited by 770
Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart
Chen, C.-H., Budas, G. R., Churchill, E. N., Disatnik, M.-H., Hurley, T. D., & Mochly-Rosen, D. (2008) · Science · doi:10.1126/science.1158554 · Cited by 767
Animal models in type 2 diabetes research: an overview.
Srinivasan, K., & Ramarao, P. (2007) · PubMed · Cited by 709
Zou, M., Shi, C., & Cohen, R. A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14442 · Cited by 685
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 1×
“However, it should be noted that concentrations of 1–100 μM of empagliflozin and other SGLT2i are frequently used in cell culture [81,82].”
RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice
Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L. L., Goova, M. T., Moser, B., Kislinger, T., Lee, D. C., et al. (2002) · Circulation · doi:10.1161/01.cir.0000039325.03698.36 · Cited by 563
Identification of the enzymatic mechanism of nitroglycerin bioactivation
Chen, Z., Zhang, J., & Stamler, J. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122225199 · Cited by 541
Targeting vascular (endothelial) dysfunction
Daiber, A., Steven, S., Weber, A., Shuvaev, V. V., Muzykantov, V. R., Laher, I., Li, H., Lamas, S., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13517 · Cited by 501 · cited 4×
“2E), which is best explained by direct oxidative inactivation of the constituents of this pathway (e.g. thiol oxidation in sGC, oxidative break-down of •NO, and oxidative depletion of BH4) [56,57] but also adverse phosphorylation of eNOS at Thr495 by protein kinase C [40,41].”
InfluentialSelf-citationBierhaus, A., Fleming, T., Stoyanov, S., Leffler, A., Babes, A., Neacsu, C., Sauer, S. K., Eberhardt, M., Schnölzer, M., Lasitschka, F., et al. (2012) · Nature Medicine · doi:10.1038/nm.2750 · Cited by 495
Zou, M.-H., Shi, C., & Cohen, R. A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214442 · Cited by 494
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483
Self-citationRAGE-Induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes
Coughlan, M. T., Thorburn, D. R., Penfold, S. A., Laskowski, A., Harcourt, B. E., Sourris, K. C., Tan, A. L. Y., Fukami, K., Thallas-Bonke, V., Nawroth, P. P., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050514 · Cited by 472
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
Oxidative stress and diabetic cardiovascular complications
Jay, D., Hitomi, H., & Griendling, K. K. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.06.018 · Cited by 464
Heitzer, T., Krohn, K., Albers, S., & Meinertz, T. (2000) · Diabetologia · doi:10.1007/s001250051551 · Cited by 427
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
Wautier, J. L., Wautier, M. P., Schmidt, A. M., Anderson, G. M., Hori, O., Zoukourian, C., Capron, L., Chappey, O., Yan, S. D., & Brett, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7742 · Cited by 353
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Alp, N. J., Mussa, S., Khoo, J., Cai, S., Guzik, T., Jefferson, A., Goh, N., Rockett, K. A., & Channon, K. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17786 · Cited by 321
Rieg, T., Masuda, T., Gerasimova, M., Mayoux, E., Platt, K., Powell, D. R., Thomson, S. C., Koepsell, H., & Vallon, V. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00518.2013 · Cited by 310
Self-citationSydow, K., Daiber, A., Oelze, M., Chen, Z., August, M., Wendt, M., Ullrich, V., Mülsch, A., Schulz, E., Keaney, J. F., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419267 · Cited by 300
Self-citationOelze, M., Kröller-Schön, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinßius, E., Agdauletova, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112394 · Cited by 293
Self-citationEvolution of β-Cell Dysfunction in the Male Zucker Diabetic Fatty Rat
Tokuyama, Y., Sturis, J., DePaoli, A. M., Takeda, J., Stoffel, M., Tang, J., Sun, X., Polonsky, K. S., & Bell, G. I. (1995) · Diabetes · doi:10.2337/diab.44.12.1447 · Cited by 281
Han, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281
Forbes, J. M., Cooper, M. E., Thallas, V., Burns, W. C., Thomas, M. C., Brammar, G. C., Lee, F., Grant, S. L., Burrell, L. M., Jerums, G., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.11.3274 · Cited by 277
Heise, T., Seewaldt‐Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., & Woerle, H. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12073 · Cited by 273
Daiber, A., Di Lisa, F., Oelze, M., Kröller‐Schön, S., Steven, S., Schulz, E., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13403 · Cited by 269
Self-citationSchulz, E., Wenzel, P., Münzel, T., & Daiber, A. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4609 · Cited by 251
Self-citationKröller-Schön, S., Steven, S., Kossmann, S., Scholz, A., Daub, S., Oelze, M., Xia, N., Hausding, M., Mikhed, Y., Zinßius, E., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4953 · Cited by 248
Self-citationMiao, F., Smith, D. D., Zhang, L., Min, A., Feng, W., & Natarajan, R. (2008) · Diabetes · doi:10.2337/db08-0645 · Cited by 247
Liang, Y., Arakawa, K., Ueta, K., Matsushita, Y., Kuriyama, C., Martin, T., Du, F., Liu, Y., Xu, J., Conway, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030555 · Cited by 240
Lin, M. I., Fulton, D., Babbitt, R., Fleming, I., Busse, R., Pritchard, K. A., & Sessa, W. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302836200 · Cited by 236
Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H.-J., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 231
Ojima, A., Matsui, T., Nishino, Y., Nakamura, N., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1395609 · Cited by 223
Wenzel, P., Schuhmacher, S., Kienhöfer, J., Müller, J., Hortmann, M., Oelze, M., Schulz, E., Treiber, N., Kawamoto, T., Scharffetter-Kochanek, K., et al. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn182 · Cited by 207
Self-citationOelze, M., Daiber, A., Brandes, R. P., Hortmann, M., Wenzel, P., Hink, U., Schulz, E., Mollnau, H., von Sandersleben, A., Kleschyov, A. L., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000239207.82326.29 · Cited by 203
Self-citationFerreira, L., Teixeira-de-Lemos, E., Pinto, F., Parada, B., Mega, C., Vala, H., Pinto, R., Garrido, P., Sereno, J., Fernandes, R., et al. (2010) · Mediators of Inflammation · doi:10.1155/2010/592760 · Cited by 193
Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V. T., Hohenstein, B., & Hugo, C. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00145.2014 · Cited by 189
Self-citationKröller-Schön, S., Knorr, M., Hausding, M., Oelze, M., Schuff, A., Schell, R., Sudowe, S., Scholz, A., Daub, S., Karbach, S., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs246 · Cited by 174
Self-citationWenzel, P., Hink, U., Oelze, M. W., Schuppan, S., Schaeuble, K., Schildknecht, S., Ho, K. K., Weiner, H., Bachschmid, M. M., Münzel, T. F., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606477200 · Cited by 157
Self-citationLi, H., Junk, . C., Huwiler, A., Burkhardt, C., Wallerath, T., Pfeilschifter, J. M., & Förstermann, U. (2002) · Circulation · doi:10.1161/01.cir.0000035650.05921.50 · Cited by 157
Self-citationOelze, M. W., Kröller‐Schön, S., Steven, S., Lubos, E., Doppler, C. E. J., Hausding, M., Tobias, S., Brochhausen, C., Li, H., Torzewski, M., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01602 · Cited by 136
Self-citationWang, J., Wang, H., Hao, P., Li, X., Wei, S., Zhang, Y. L., & Chen, Y. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00114 · Cited by 135
Cassuto, J. R., Dou, H., Czikora, I., Szabo, A., Patel, V. S., Kamath, V. M., de Chantemèle, E. J. B., Fehér, A., Romero, M. J., & Bagi, Z. A. (2013) · Diabetes · doi:10.2337/db13-0577 · Cited by 126
Apaijai, N., Pintana, H., Chattipakorn, S. C., & Chattipakorn, N. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12176 · Cited by 116
Scheen, A. J., & Paquot, N. (2014) · Diabetes & Metabolism · doi:10.1016/s1262-3636(14)72689-8 · Cited by 115
Wenzel, P., Schulz, E., Oelze, M. W., Müller, J., Schuhmacher, S., Alhamdani, M. S. S., Debrezion, J., Hortmann, M., Reifenberg, K., Fleming, I., et al. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.05.009 · Cited by 115
Self-citationA Novel Rat Model of Type 2 Diabetes: The Zucker Fatty Diabetes Mellitus ZFDM Rat
Yokoi, N., Hoshino, M., Hidaka, S., Yoshida, E., Beppu, M., Hoshikawa, R., Sudo, K., Kawada, A., Takagi, S., & Seino, S. (2013) · Journal of Diabetes Research · doi:10.1155/2013/103731 · Cited by 112
Site-Specific Analysis of Histone Methylation and Acetylation
Umlauf, D., Goto, Y., & Feil, R. (2004) · Humana Press eBooks · doi:10.1385/1-59259-828-5:099 · Cited by 95
Cheng, S. T. W., Chen, L., Li, S. Y. T., Mayoux, E., & Leung, P. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147391 · Cited by 90
Self-citationWenzel, P., Müller, J., Zurmeyer, S., Schuhmacher, S., Schulz, E., Oelze, M. W., Pautz, A., Kawamoto, T., Wojnowski, L., Kleinert, H., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.12.089 · Cited by 86
Self-citationLuippold, G., Klein, T., Mark, M., & Grempler, R. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01569.x · Cited by 79
Hausding, M., Jurk, K., Daub, S., Kröller‐Schön, S., Stein, J., Schwenk, M., Oelze, M. W., Mikhed, Y., Kerahrodi, J. G., Kossmann, S., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0386-5 · Cited by 78
Self-citationRoles of the AGE‐RAGE System in Vascular Injury in Diabetesa
Yamamoto, Y., Yamagishi, S., Yonekura, H., Doi, T., Tsuji, H., KATO, I., Takasawa, S., OKAMOTO, H., Abedin, J., Tanaka, N., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06311.x · Cited by 69
Sun, M., Yokoyama, M., Ishiwata, T., & Asano, G. (1998) · PubMed · Cited by 67
Brandt, M., Garlapati, V. S., Oelze, M. W., Sotiriou, E., Knorr, M., Kröller‐Schön, S., Kossmann, S., Schönfelder, T., Morawietz, H., Schulz, E., et al. (2016) · Scientific Reports · doi:10.1038/srep32554 · Cited by 65
Self-citationVickers, S. P., Cheetham, S. C., Headland, K. R., Dickinson, K., Grempler, R., Mayoux, E., Mark, M., & Klein, T. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s58786 · Cited by 62
Self-citationHansen, H. H., Jelsing, J., Hansen, C. F., Hansen, G., Vrang, N., Mark, M., Klein, T., & Mayoux, E. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213454 · Cited by 61
Self-citationChen, L., Klein, T., & Leung, P. S. (2012) · Current Molecular Medicine · doi:10.2174/156652412802480970 · Cited by 49
Oelze, M. W., Knorr, M., Schuhmacher, S., Heeren, T. F. C., Otto, C., Schulz, E., Reifenberg, K., Wenzel, P., Münzel, T. F., & Daiber, A. (2011) · Journal of Vascular Research · doi:10.1159/000320627 · Cited by 49
Self-citationKuriyama, C., Xu, J., Lee, S. P., Qi, J., Kimata, H., Kakimoto, T., Nakayama, K., Watanabe, Y., Taniuchi, N., Hikida, K., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.217992 · Cited by 48
Aging and Insulin Resistance: Just Say iNOS
Evans, J. L., & Goldfine, I. D. (2013) · Diabetes · doi:10.2337/db12-1239 · Cited by 47
Jufvas, Å., Sjödin, S., Lundqvist, K., Amin, R., Vener, A. V., & Strålfors, P. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-15 · Cited by 45
Wu, Z., Siuda, D., Xia, N., Reifenberg, G., Daiber, A., Münzel, T. F., Förstermann, U., & Li, H. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04416 · Cited by 43
Self-citationWatanabe, Y., Nakayama, K., Taniuchi, N., Horai, Y., Kuriyama, C., Ueta, K., Arakawa, K., Senbonmatsu, T., & Shiotani, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116851 · Cited by 39
Thomas, L. H., Tadayyon, M., & Mark, M. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143966 · Cited by 32
Fala, L. (2015) · PubMed · Cited by 30
Native Chromatin Immunoprecipitation
Cosseau, C., & Grunau, C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-316-5_15 · Cited by 30
Tekabe, Y., Anthony, T., Li, Q., Ray, R., Rai, V., Zhang, G., Schmidt, A. M., & Johnson, L. L. (2015) · Vascular Medicine · doi:10.1177/1358863x14568337 · Cited by 17
Blockade of RAGE in Zucker obese rats with experimental periodontitis
Grauballe, M. B., Østergaard, J. A., Schou, S., Flyvbjerg, A., & Holmstrup, P. (2016) · Journal of Periodontal Research · doi:10.1111/jre.12373 · Cited by 12
Wölkart, G., Beretta, M., Wenzl, M. V., Stessel, H., Schmidt, K., Maeda, N., Mayer, B., & Schrammel, A. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12081 · Cited by 11
Bassirat, M., & Khalil, Z. G. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.10.001 · Cited by 10
Cited by
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.005 · Cited by 1,787
“A shift in fuel substrate metabolism from glucose to NEFAs and ketones, including by the myocardium, is 1 of the mechanisms by which SGLT2 inhibitors may provide cardiovascular protection,(107) but studies in apoE knockout mice and Zucker diabetic fatty rats suggest that anti-inflammatory effects may also play a role.…”
BackgroundVascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
Self-citationLi, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
“Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was recently developed as an anti-diabetic agent to promote urinal glucose excretion or glycosuria in an insulin-independent manner [5,6].”
BackgroundBonnet, F., & Scheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.09.005 · Cited by 308
Metadata
- Authors
- Steven, S., Oelze, M., Hanf, A., Kröller-Schön, S., Kashani, F., Roohani, S., Welschof, P., Kopp, M., Gödtel-Armbrust, U., Xia, N., Li, H., Schulz, E., Lackner, K. J., Wojnowski, L., Bottari, S. P., Wenzel, P., Mayoux, E., Münzel, T., & Daiber, A.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 13
- Pages
- 370-385
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W2653398740
- Cited by
- 298
- References
- 83
- FWCI
- 16.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.